Overview and Scope
Duchenne muscular dystrophy (DMD) therapeutics refers to the various medical treatments and interventions aimed at managing and alleviating the symptoms of duchenne muscular dystrophy, a genetic disorder characterized by progressive muscle weakness and degeneration. These therapeutic approaches are designed to slow disease progression, improve muscle function and enhance the overall quality of life for individuals with duchenne muscular dystrophy.
Sizing and Forecast
The duchenne muscular dystrophy (dmd) therapeutics market size has grown exponentially in recent years. It will grow from $8.64 billion in 2023 to $11.95 billion in 2024 at a compound annual growth rate (CAGR) of 38.4%. The growth in the historic period can be attributed to increasing prevalence of duchenne muscular dystrophy, awareness about duchenne muscular dystrophy treatment, rising healthcare spending, government initiatives.
The duchenne muscular dystrophy (dmd) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $36.72 billion in 2028 at a compound annual growth rate (CAGR) of 32.4%. The growth in the forecast period can be attributed to growing investments in for duchenne muscular dystrophy treatments, adoption of combination therapies, emergence of biomarker,growing number of screening programs for duchenne muscular dystrophy. Major trends in the forecast period include innovative treatments for duchenne muscular dystrophy, development of targeted therapies, introduction of novel medications and therapies, innovative disease-modifying therapies, active drug developments.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-dmd-therapeutics-global-market-report
Segmentation & Regional Insights
The duchenne muscular dystrophy (dmd) therapeutics market covered in this report is segmented –
1) By Type: Small Molecules; Biologics
2) By Distribution Channel: Offline; Online
3) By Application: Hospitals; Clinics; Home Care
North America was the largest region in the DMD therapeutics market in 2023. The regions covered in duchenne muscular dystrophy (DMD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12916&type=smp
Major Driver Impacting Market Growth
The rising number of clinical trials is expected to propel the growth of the Duchenne muscular dystrophy (DMD) therapeutics market going forward. Clinical trials are research studies conducted on human participants to evaluate the safety, efficacy and potential benefits of new medical treatments, interventions, or drugs. The surge in clinical trials focusing on Duchenne muscular dystrophy treatment signifies continuous research, innovation and a wide array of therapeutic possibilities, all of which are expected to enhance patient outcomes, attract investments and expedite the advancement and Availability of Effective Therapies for Duchenne Muscular Dystrophy (DMD). For Instance, In August 2023, according to Clinicaltrials.Gov, a part of The National Institutes Of Health (NIH), a US-based government agency responsible for conducting and supporting medical research, the number of registered clinical trials increased to 464,218 compared to 399,496 in 2021 in all 50 states of the United States and across 221 countries. Moreover, it was reported that 142,700 studies (31% of the total) are registered in the U.S., while 248,310 studies (53% of the total) are recorded in non-U.S. locations. Therefore, a rising number of clinical trials will drive the growth of the duchenne muscular dystrophy (DMD) therapeutics market.
Key Industry Players
Major players in the duchenne muscular dystrophy (dmd) therapeutics market are CVS Health Corporation, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Eli Lilly and Co., Otsuka Holdings Co. Ltd., Daiichi Sankyo Co. Ltd., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., CRISPR Therapeutics AG, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Halozyme Therapeutics Inc., FibroGen Inc., Exonics Therapeutics Inc., Italfarmaco S.p.A., Wave Life Sciences Ltd., MeiraGTx Holdings PLC, Editas Medicine Inc., NS Pharma Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc.
The duchenne muscular dystrophy (dmd) therapeutics market report table of contents includes:
1. Executive Summary
2.Duchenne Muscular Dystrophy (DMD) Therapeutics Market Characteristics
3.Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends And Strategies
4.Duchenne Muscular Dystrophy (DMD) Therapeutics Market analysis
5.Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size And Growth
6.Duchenne Muscular Dystrophy (DMD) Therapeutics Segmentation
7.Duchenne Muscular Dystrophy (DMD) Therapeutics Regional And Country Analysis
.
.
.
27.Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Landscape And Company Profiles
28.Duchenne Muscular Dystrophy (DMD) Therapeutics Key Mergers And Acquisitions
29.Duchenne Muscular Dystrophy (DMD) Therapeutics Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- CVS Health Corporation
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
